|Side effects||Seizures, slurred speech, trouble sleeping, confusion, depression|
|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||302.290 g·mol−1|
|3D model (JSmol)|
Terizidone (Trd) is an antibiotic used to treat tuberculosis. Specifically it is used in multi-drug-resistant tuberculosis (MDR-TB) when other agents are not suitable. It is used together with other tuberculosis medication and vitamin B6. It is generally take by mouth for about 2 years.
Side effects may include seizures, slurred speech, trouble sleeping, confusion, and depression. Side effects are believed to be less than the similar medication cycloserine. It should not be used in those with significant kidney problems. It works by stoping bacterial growth after being broken down into cycloserine.
The medication may be available from the Stop TB Partnership. It is not available in the United States. It is on the World Health Organization's List of Essential Medicines as an alternative to cycloserine. As of 2015, 50 tablets of 250 mg costs about 80 USD.
- Ramanathan, Meenakshi R. (2019). "Chapter 28 - Drugs in tuberculosis and leprosy". Side Effects of Drugs Annual. Elsevire. pp. 321–338. Archived from the original on 8 May 2023. Retrieved 12 September 2023.
- "TERIZIDON, 250 mg, capsules, hard" (PDF). Archived (PDF) from the original on 13 September 2023. Retrieved 12 September 2023.
- Abraham, Donald J. (2021). Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set. John Wiley & Sons. ISBN 9781119530305. Archived from the original on 2023-09-13. Retrieved 2023-09-12.
- The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2015. WHO. 2015. p. 34. ISBN 9789241209946. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.